Allison S.Y. Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allison S.Y. Chan has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Anand Devaprasath Jeyasekharan
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
5 shared publications - Shruti Sridhar
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
4 shared publications - Angie Tan
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore
3 shared publications - Aurelien Pelissier
Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, USA
3 shared publications - Chang Li
10Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut
3 shared publications - Choong-Kun Lee
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
3 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- Open Access
- 7 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4922-4935
Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in the gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune features associated with CLDN18.2 expression status. Experimental Design: Tumor-immune features were profiled in 103 patients with HER2-neg/low advanced gastric cancer treated with first-line immune checkpoint inhibitor (ICI) using multiplex immunohistochemistry [7,423,483 cells across 2,315 regions of interest (ROI)]. The findings were validated in five published whole-transcriptome sequencing/microarray cohorts (1,521 samples), including the landmark CheckMate 649 phase III trial. Spatial immune architecture was assessed by cellular neighborhood analysis. Digital spatial profiling (DSP) was performed on 480 ROIs from a CLDN18.2-annotated tissue microarray (75 patients). Results: CLDN18.2high tumors showed reproducible enrichment of humoral pathways, with higher CD20+ B-cell density and enrichment of B-cell/plasma-cell signatures. CLDN18.2 status alone was not associated with response or survival on first-line ICI therapy; in CLDN18.2low tumors, B-cell enrichment was associated with ICI benefit, unlike CLDN18.2high tumors. Spatial analyses indicated that CLDN18.2high tumors preferentially harbored tumor-infiltrating B cells, rather than tertiary lymphoid structure/lymphoid aggregate–like neighborhoods, and this tumor-compartment localization was associated with diminished ICI benefit. DSP confirmed that CD20+ B-cell enrichment was most pronounced within tumor regions, alongside compartment-specific activation of humoral and extrafollicular response programs and interferon-associated and remodeling signatures. Conclusions: CLDN18.2high gastric cancer exhibits a humoral-enriched microenvironment with increased tumor-infiltrating B cells and spatial immune organization associated with reduced ICI benefit. Spatial and humoral-state biomarkers may inform ongoing CLDN18.2-directed combination trials.
- 7 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4922-4935
Open AccessSpatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in the gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune features associated with CLDN18.2 expression status. Experimental Design: Tumor-immune features were profiled in 103 patients with HER2-neg/low advanced gastric cancer treated with first-line immune checkpoint inhibitor (ICI) using multiplex immunohistochemistry [7,423,483 cells across 2,315 regions of interest (ROI)]. The findings were validated in five published whole-transcriptome sequencing/microarray cohorts (1,521 samples), including the landmark CheckMate 649 phase III trial. Spatial immune architecture was assessed by cellular neighborhood analysis. Digital spatial profiling (DSP) was performed on 480 ROIs from a CLDN18.2-annotated tissue microarray (75 patients). Results: CLDN18.2high tumors showed reproducible enrichment of humoral pathways, with higher CD20+ B-cell density and enrichment of B-cell/plasma-cell signatures. CLDN18.2 status alone was not associated with response or survival on first-line ICI therapy; in CLDN18.2low tumors, B-cell enrichment was associated with ICI benefit, unlike CLDN18.2high tumors. Spatial analyses indicated that CLDN18.2high tumors preferentially harbored tumor-infiltrating B cells, rather than tertiary lymphoid structure/lymphoid aggregate–like neighborhoods, and this tumor-compartment localization was associated with diminished ICI benefit. DSP confirmed that CD20+ B-cell enrichment was most pronounced within tumor regions, alongside compartment-specific activation of humoral and extrafollicular response programs and interferon-associated and remodeling signatures. Conclusions: CLDN18.2high gastric cancer exhibits a humoral-enriched microenvironment with increased tumor-infiltrating B cells and spatial immune organization associated with reduced ICI benefit. Spatial and humoral-state biomarkers may inform ongoing CLDN18.2-directed combination trials.
- 28 April 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (4) , 288-292
Single-cell Resolved Oncogene Co-expression: From Principles to Clinical Impact
Summary: This commentary explores the concept and utility of studying oncogene co-expression at single-cell resolution and its clinical and biological implications. We emphasize the importance of scalable methods, mathematically driven quantification models, and artificial intelligence integration to enhance the clinical utility of this approach.
- 28 April 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (4) , 288-292
Single-cell Resolved Oncogene Co-expression: From Principles to Clinical Impact
Summary: This commentary explores the concept and utility of studying oncogene co-expression at single-cell resolution and its clinical and biological implications. We emphasize the importance of scalable methods, mathematically driven quantification models, and artificial intelligence integration to enhance the clinical utility of this approach.
- Open Access
Genotoxic chemotherapy impedes complement dependent cytotoxicity via Chk1-mediated CD59 regulation
DNA damage responses primarily coordinate intracellular processes, but their effects on the cell surface remain poorly understood. We uncovered a DNA damage response at the cell surface that regulates complement dependent cytotoxicity (CDC), a key mechanism of antibody-mediated tumor cell killing. We found that several mCRPs, such as CD46, CD55, and CD59, are upregulated in diffuse large B-cell lymphoma (DLBCL) cells following chemotherapy. These mCRPs protect cells from CDC, including CDC triggered by anti-CD20 immunotherapy. Chemotherapy pre-treatment reduced the efficacy of rituximab-induced CDC, with CD59 exerting a dominant function. A high-throughput kinase screen revealed that Chk1 inhibition restored CDC sensitivity. Mechanistically, chemotherapy-induced CD59 expression was Chk1-dependent and regulated at an Sp1-driven promoter site. Inhibition of Sp1 with Mithramycin A abrogated chemotherapy-induced CD59 transcription. Co-immunoprecipitation mass spectrometry revealed that DNA damage releases transcriptional repressors from Sp1, an effect reversed by Chk1 inhibition. These findings define a Chk1-Sp1-CD59 signaling axis linking genotoxic stress to complement modulation. Our study reveals potential antagonism between chemotherapy and antibody-mediated CDC and highlights consideration in sequencing combination therapies and a therapeutic potential of Chk1 inhibitors in maintaining CDC efficacy during chemoimmunotherapy. Short Summary Rituximab-based chemoimmunotherapy is the first-line treatment for DLBCL. Our study reveals that chemotherapy induces resistance to rituximab-mediated cell killing. We identify this resistance as driven by a Chk1-Sp1-CD59 signaling axis and provide a therapeutic rationale for targeting this pathway to enhance chemoimmunotherapy efficacy.
Open AccessGenotoxic chemotherapy impedes complement dependent cytotoxicity via Chk1-mediated CD59 regulation
DNA damage responses primarily coordinate intracellular processes, but their effects on the cell surface remain poorly understood. We uncovered a DNA damage response at the cell surface that regulates complement dependent cytotoxicity (CDC), a key mechanism of antibody-mediated tumor cell killing. We found that several mCRPs, such as CD46, CD55, and CD59, are upregulated in diffuse large B-cell lymphoma (DLBCL) cells following chemotherapy. These mCRPs protect cells from CDC, including CDC triggered by anti-CD20 immunotherapy. Chemotherapy pre-treatment reduced the efficacy of rituximab-induced CDC, with CD59 exerting a dominant function. A high-throughput kinase screen revealed that Chk1 inhibition restored CDC sensitivity. Mechanistically, chemotherapy-induced CD59 expression was Chk1-dependent and regulated at an Sp1-driven promoter site. Inhibition of Sp1 with Mithramycin A abrogated chemotherapy-induced CD59 transcription. Co-immunoprecipitation mass spectrometry revealed that DNA damage releases transcriptional repressors from Sp1, an effect reversed by Chk1 inhibition. These findings define a Chk1-Sp1-CD59 signaling axis linking genotoxic stress to complement modulation. Our study reveals potential antagonism between chemotherapy and antibody-mediated CDC and highlights consideration in sequencing combination therapies and a therapeutic potential of Chk1 inhibitors in maintaining CDC efficacy during chemoimmunotherapy. Short Summary Rituximab-based chemoimmunotherapy is the first-line treatment for DLBCL. Our study reveals that chemotherapy induces resistance to rituximab-mediated cell killing. We identify this resistance as driven by a Chk1-Sp1-CD59 signaling axis and provide a therapeutic rationale for targeting this pathway to enhance chemoimmunotherapy efficacy.